Synonyms: N-Benzyl-N-hydroxy-2,2-dimethylbutanamide; RIPA56
Molecular Formula: C13H19NO2
Molecular Weight: 221.3
Linear Structural Formula: C13H19NO2
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: RIPA-56 is a metabolically stable type III kinase inhibitor that targets receptor-interacting protein 1 kinase (RIP1; RIPK1) in a highly potent and selective manner (RIP1 IC50 = 13 nM) by locking RIP1 in its inactive form, exhibiting no inhibitory potency toward RIP3, IDO or a panel of multiple kinases (tested at 10, 200, and 5 muM, respectively). RIPA-56 protects against TNFalpha-induced necroptosis (necrosis) upon apoptosis/NF-kappaB pathway blockage (EC50 = 27 nM/murine L929 and 28 nM/human HT-29 cells) in cultures as well as TNFalpha-induced mortality and multiorgan damage in a murine model of systemic inflammatory response syndrome (SIRS) in vivo (100% survival rate with 3 mg/kg/12 h or single 6 mg/kg i.p.) with good pharmacokinetics and bioavailability (F post 10 mg/kg p.o. or i.p. dosing = 22% and 100%, respectively, of 2 mg/kg i.v.). Long-term daily RIPA-56 supplementation (150 or 300 mg/kg in chow) is reported to prevent aging-associated deterioration of the male reproductive system in mice.